Grace Therapeutics, Inc. SEC filings GRCE
Grace Therapeutics, Inc. has 594 filings in SEC EDGAR's recent list, going back to Sep 2, 2008. Its latest annual report, Form 10-K, was filed on Jun 18, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 31, 2026 | — |
| D | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Mar 13, 2025 | — |
| CORRESP | Letter to the SEC | Mar 12, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| D | Filing | Feb 25, 2025 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| EFFECT | Filing | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Jul 31, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| EFFECT | Filing | Oct 16, 2023 | — |
| CORRESP | Letter to the SEC | Oct 12, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2023 | — |
| D | Filing | Oct 10, 2023 | — |
| 425 | Filing | Aug 12, 2021 | — |
| 425 | Filing | Aug 4, 2021 | — |
| 425 | Filing | Aug 4, 2021 | — |
| 425 | Form 8-k | Jul 23, 2021 | — |
| 425 | Form 8-k | Jul 21, 2021 | — |
| EFFECT | Filing | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2021 | — |
| 425 | Form 8-k | May 7, 2021 | — |
| EFFECT | Filing | Jul 7, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2020 | — |
| EFFECT | Filing | Aug 9, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2019 | — |
| CORRESP | Letter to the SEC | Aug 8, 2019 | — |
| EFFECT | Filing | Jul 17, 2019 | — |
| EFFECT | Filing | Oct 17, 2018 | — |
| CORRESP | Letter to the SEC | Oct 12, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2018 | — |
| D | Filing | May 25, 2018 | — |
| EFFECT | Filing | Mar 16, 2018 | — |
| CORRESP | Letter to the SEC | Mar 15, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2018 | — |
| EFFECT | Filing | Dec 19, 2017 | — |
| CORRESP | Letter to the SEC | Dec 19, 2017 | — |
| CORRESP | Letter to the SEC | Dec 19, 2017 | — |
| CORRESP | Letter to the SEC | Nov 16, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2017 | — |
| SUPPL | Prospectus supplement | Nov 29, 2013 | — |
| SUPPL | Preliminary prospectus supplement | Nov 26, 2013 | — |
| EFFECT | Filing | Oct 28, 2013 | — |
| CERTNAS | Auto-generated paper document | Jan 4, 2013 | — |
| 8-A12B | Form 8-a | Jan 4, 2013 | — |
| 40FR12G/A | Form 40-fr12/a | Jul 24, 2012 | — |
| 40FR12G | Form 40-f | Jul 20, 2012 | — |
| CERTNAS | Auto-generated paper document | Jan 4, 2012 | — |
| D | Filing | Sep 2, 2011 | — |
| CB | Form cb | Sep 2, 2008 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRCE (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1444192
- Former names
- Acasti Pharma Inc. (until Oct 25, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.